NeOnc Technologies Holdings is trading at $3.35, down 11.24%, with biotech weakness and financing overhang likely adding pressure.

  • No new company-specific announcement directly explains the September 15 decline; the reported CEO purchase was supportive but not linked to the selloff.
  • The recent $15 million registered direct offering included approximately 3.57 million shares and warrants for another 3.57 million shares at $4.20, creating potential dilution and financing overhang.
  • Broader risk-off trading likely added pressure, with XBI down 2.11%.